Table 3.

Association between NOS1AP genotype and cardiovascular mortality (n = 54) in 1113 incident calcium channel blocker users

		Model 1*		Model 2†		Model 3‡
	Cases	HR	(95% CI)	HR	(95% CI)	HR	(95% CI)
Dihydropyridine calcium channel blockers (n = 38)
TT	7	Ref.		Ref.		Ref.
TG	22	3.51	(1.41, 8.78)	3.40	(1.36, 8.51)	3.33	(1.32, 8.39)
GG	9	6.00	(1.80, 20.0)	5.91	(1.77, 19.7)	6.38	(1.38, 22.2)
Amlodipine
TT	2	Ref.		Ref.		Ref.
TG	6	2.39	(0.47, 12.1)	2.41	(0.47, 12.3)	2.23	(0.44, 11.3)
GG	3	4.49	(0.73, 27.8)	2.99	(0.47, 19.3)	3.23	(0.48, 21.7)
Nifedipine
TT	4	Ref.		Ref.		Ref.
TG	12	4.98	(1.32, 18.9)	5.22	(1.34, 20.3)	5.90	(1.49, 23.4)
GG	5	11.0	(1.13, 107)	8.80	(0.84, 92.0)	14.7	(1.17, 184)
Nondihydropyridine calcium channel blockers (n = 16)
TT	8	Ref.		Ref.		Ref.
TG	5	0.85	(0.26, 2.80)	0.83	(0.25, 2.75)	0.77	(0.23, 2.63)
GG	3	1.10	(0.21, 5.77)	1.10	(0.21, 5.83)	1.12	(0.18, 6.85)
Verapamil
TT	3	Ref.		Ref.		Ref.
TG	1	0.49	(0.04, 6.09)	0.43	(0.03, 5.29)	0.56	(0.03, 8.92)
GG	1	–§		–§		–§
Diltiazem
TT	5	Ref.		Ref.		Ref.
TG	4	1.01	(0.25, 4.08)	1.02	(0.25, 4.10)	0.96	(0.21, 4.26)
GG	2	1.57	(0.27, 9.18)	1.48	(0.26, 8.45)	1.41	(0.19, 10.7)

^*Model 1: adjusted for age and gender.

^†Model 2: adjusted for age, gender and QTc interval.

^‡Model 3: adjusted for age, gender, QTc interval, hypertension and diabetes mellitus.

^§Numbers were too low to calculate hazard ratios.